Citation Impact
Citing Papers
Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
2008 Standout
Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney
2006 StandoutNobel
Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy
2010 StandoutNobel
Angiotensin II Activates the Proinflammatory Transcription Factor Nuclear Factor-κB in Human Monocytes
1999
Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine
1991
Epicardial vasomotor responses to acetylcholine are not predicted by coronary atherosclerosis as assessed by intracoronary ultrasound
1995
Improved Left Ventricular Function After Chronic Left Ventricular Unloading
1996
The Failing Heart — An Engine Out of Fuel
2007 Standout
Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction
1992 Standout
Prospects for Cardiovascular Research
2001 StandoutNobel
Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy
2001 Standout
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
2003 Standout
Role of aldosterone in the remnant kidney model in the rat.
1996
Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
2001 Standout
Coronary vasoconstriction induced by mental stress (simulated public speaking)
1995
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients
2000
Endothelial function as a determinant of vascular function and structure: A new therapeutic target
1997
Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients
1993
The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure
2005 Standout
Amiodarone in Patients with Congestive Heart Failure and Asymptomatic Ventricular Arrhythmia
1995
Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo
1991 Standout
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
2001 Standout
Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
2002 Standout
Effect of Carvedilol on Survival in Severe Chronic Heart Failure
2001 Standout
Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system
2005 StandoutNobel
Improved Survival with an Implanted Defibrillator in Patients with Coronary Disease at High Risk for Ventricular Arrhythmia
1996 Standout
Randomised trial of low-dose amiodarone in severe congestive heart failure
1994
Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E–deficient mice
2000 Standout
The L-Arginine-Nitric Oxide Pathway
1993 Standout
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
1992 Standout
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
Effects of Multisite Biventricular Pacing in Patients with Heart Failure and Intraventricular Conduction Delay
2001 Standout
Treatment of Hypertension in Patients 80 Years of Age or Older
2008 Standout
Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk
2003 Standout
Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation
1990
Improving survival for patients with advanced heart failure: A study of 737 consecutive patients
1995
Inflammation in atherosclerosis
2002 StandoutNature
Pleiotropic effects of statin therapy: molecular mechanisms and clinical results
2008
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
2014 Standout
Progress and challenges in translating the biology of atherosclerosis
2011 StandoutNature
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
1999 Standout
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
1992 Standout
Inflammation, Atherosclerosis, and Coronary Artery Disease
2005 Standout
Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions.
1993
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
2003 Standout
Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress
2005 Standout
Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice
1999 StandoutNobel
Enhanced atherosclerosis and kidney dysfunction in eNOS–/–Apoe–/– mice are ameliorated by enalapril treatment
2000 StandoutNobel
MODULATION OF VASOCONSTRICTION BY ENDOTHELIUM‐DERIVED NITRIC OXIDE: THE INFLUENCE OF VASCULAR DISEASE
1995
Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure
2005 Standout
The Tumor Necrosis Factor Ligand and Receptor Families
1996 StandoutNobel
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
2010 Standout
Anti‐remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN‐CHF study): final results
2009
Long-Term Follow-Up of Patients With Mild Coronary Artery Disease and Endothelial Dysfunction
2000 Standout
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
Chronic Heart Failure in the United States
1998
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
2002 Standout
Guidelines for the early management of patients with acute myocardial infarction
1990
Prophylactic antiarrhythmic therapy of high-risk survivors of myocardial infarction: lower mortality at 1 month but not at 1 year.
1987
Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation
2001 Standout
Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures
2001
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials
2004
Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist Device
2009 Standout
Angiotensin-Converting Enzyme Inhibition With Quinapril Improves Endothelial Vasomotor Dysfunction in Patients With Coronary Artery Disease
1996
Protection of the Arterial Internal Elastic Lamina by Inhibition of the Renin-Angiotensin System in the Rat
1998
Early evidence of endothelial vasodilator dysfunction at coronary branch points.
1990
Intracoronary Adenovirus-Mediated Delivery and Overexpression of the β 2 -Adrenergic Receptor in the Heart
2000 StandoutNobel
Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril
2001
Coronary Plaque Disruption
1995 Standout
Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
2000 Standout
Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes
2003 Standout
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials
2000
Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis.
1991
Endothelial cells in physiology and in the pathophysiology of vascular disorders.
1998 Standout
The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction
2001
1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension
1999 Standout
Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system
2005 StandoutNobel
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
2002 Standout
Sustained Reduction of Aldosterone in Response to the Angiotensin Receptor Blocker Valsartan in Patients With Chronic Heart Failure
2003
Works of B. Pitt being referenced
Safety of Helicopter Transport and Out‐of‐Hospital Intravenous Fibrinolytic Therapy in Patients With Evolving Myocardial Infarction
1986
Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy
1991
Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet
1993
Complex ventricular arrhythmias after myocardial infarction during convalescence and follow-up: a harbinger of multi-vessel coronary disease, left ventricular dysfunction and sudden death.
1981
?Escape? of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy
1995
Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease.
1989
Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.
1994